

7RP SMB relaterte utlysninger innen Health og IMI

Health – 4. utlysning, IMI – 2. utlysning
Biotekforum 13. oktober 2009
Seniorrådgiver Berit Nygaard

Health (2007 – 2013)

Overordnet mål

- Bedre helsen for Europas innbyggere
- Øke konkurranseevnen for europeisk helserelatert industri
- Adressere globale helseutfordringer
(inkludert epidemier)



Health struktur og innhold



Temaer på tvers: SMB, barnehelse, helsen til den
aldrende befolkningen og kjønnsrelaterte helsespørsmål

Activity (pillar) 4: **Other actions across the theme**

4. utlysning i Health publisert 30. juli – 2010 budsjettet

Spesielt for denne utlysningen:

- Totalt 638 mill Euro for hele utlysningen
- Africa-topics
- Influenza-topics
- Mange flere totrinns topics enn tidligere utlysninger
- Mange topics innenfor kreft – obs søknadsfrister
- Ingen topics innenfor diabetes og overvekt
- SMB-deltakelse viktig
- Translasjonsforskning

1. Biotechnology, generic tools and medical technologies for human health

1) High throughput research

- Harmonisation of phenotyping and biosampling for human large-scale research biobanks
- High-throughput analysis of post-translational modifications of proteins

2) Detection, diagnosis and monitoring

- Tools for the identification and the detection of biomarkers in clinical samples and patients
- Stratification approaches and methodologies to select from a wide range of biomarkers relevant candidates for clinical validation

3) Suitability, safety, efficacy of therapies


Prosjektene på dette feltet er plassert under 4.2

4) Innovative therapeutic approaches and interventions

- Translational research on cell-based immunotherapy



2. Translating research for human health



1.1. Integrating biological data and processes ()

Large scale data Gathering (**obs 2 topics**)

- Coordination action(s) on standards in large scale data gathering



1.2. Systems Biology

- Tackling human diseases through systems biology approaches





2. Translating research for human health forts.

2) Research on the brain and related diseases, human development and ageing

- **Nevrosykdommer** – ingen topics (endret fra forrige utkast til arbeidsprogram!)


- **Aldring:**

4 topics two-stage

- Role of early-life developmental processes in longevity determination
- Integrative systems biology and comparative genomics for studying human ageing

1 topic single stage

- Ikke SMB-relevant



2. Translating research for human health

2.3 Translational research in major *infectious diseases* - to confront major threats to public health

Anti-microbial drug resistance: 0 topics i denne utlysningen

HIV&AIDS, malaria and tuberculosis (4)

- Target characterisation and hit-to-lead progression in tuberculosis
- Lead optimisation and late preclinical development in TB drugs
- European network of cohort studies on HIV/AIDS

Potentially new and re-emerging epidemics (4)

- Drug lead discovery against RNA viruses
- **Influenza call** - Novel therapeutics against influenza

Neglected infectious diseases (3 topics)

- Vaccines for childhood bacterial diarrhoeal diseases
- Comprehensive control of Neglected Infectious Diseases






2. Translating research for human health

2.4 Translational research in other major diseases

- **Cancer: (9)**


- Structuring translational cancer research between cancer research centres in Europe
- Structuring clinical research in paediatric and adolescent oncology in Europe
- Infectious agents and cancer in Africa
- translational research on cancers with poor prognosis.
- Prediction individual response and resistance to cancer therapy
- Optimising the delivery of (chemo)radiotherapy and/or surgery to cancer patients





2. Translating research for human health forts

- **Cardiovascular diseases:** (4 topics)
 - Reducing in-stent thrombosis
 - Identifying new therapeutic targets in atrial fibrillation
 - Diastolic heart failure
- **Diabetes and obesity** :- 0 topics i denne utlysningen
- **Rare diseases** (2 topics)
 - Clinical development of substances with a clear potential as orphan drugs
- **Other chronic diseases** (2 topics)
 - Infection as the trigger for the development of inflammatory processes in allergies and autoimmune diseases
 - Infection and dysbiosis as the triggers of the development of inflammatory processes in allergies and autoimmune diseases.



3. Optimising the delivery of healthcare to European citizens

3.1 Translating the result of clinical research outcome into clinical practice (1)


3,2 Quality, efficiency and solidarity of healthcare systems (2)

- Risk adjustment algorithms for better health insurance coverage

3.3 Enhanced health promotion and disease prevention

No topics

3.4 International Public Health & Health Systems (7)





4. Other actions across the health theme

1. Coordination and Support Actions across the Theme


- Promoting participation of high-technology research-intensive SME's, operating in the Health sector

2. Responding to EU Policy Needs

- Off-Patents Medicines for Children
- International paediatric initiative

Alternative testing strategies (7) - Samarbeid med kosmetikkindustrien (COLIPA)

"Where appropriate, active participation of small and medium-sized enterprises (SME's) is strongly recommended.."



Topics Alternative testing strategies – 7 topics

- Optimisation of current methodologies and development of novel methods to achieve functional differentiation of human-based target cells in vitro
- Exploitation of organ-simulating cellular devices as alternatives for long-term toxicity testing
- Establishment of endpoints and intermediate markers in human-based target cells with relevance for repeated dose systemic toxicity testing
- Computational modelling and estimation techniques
- Systems biology for the development of predictive causal computer models
- Integrated data analysis and servicing
- Coordination action

2010-utlysningen – søknadsfrister for Health og IMI

- To hovedutlysninger
 - Single-stage (40 topics) – søknadsfrist 19. november 2009
 - Two-stage (13 topics) – søknadsfrist 29. oktober 2009 (stage 1)
- *Spesielle* utlysninger

<i>Utlysning</i>	<i>Topics</i>	<i>Søknadsfrist</i>
Africa (Health, Food, Environment)	6	14. Januar 2010
Influenza (Health, Food)	1	29. Oktober 2009
Alternative utprøvningsstrategier (samarbeid med kosmetikkindustrien)	6	3. Februar 2010
IMI Lyses ut 30. oktober		29. Januar 2010 (antagelig)

Samarbeid på tvers av grenser og andre barrierer



- Samarbeid mellom land
 - Multinasjonale konsortier, med minst 3 partnere fra 27 EU medlemsland + assosierte land (Albania, Kroatia, Island, Israel, Lichtenstein, Montenegro, Norge, Serbia, Sveits og Tyrkia)
 - Forskere fra **hvor som helst i verden** kan delta
 - MEN forskere fra høyindustrialiserte land utenfor Europa kan bare i sjeldne tilfelle få finansiering (for eksempel Australia, Canada, Japan, Korea, New Zealand, **USA**), men i *Health* kan amerikanske forskere delta og få finansiering



Health – resultater i EU's 7 rammeprogram

<i>Health</i> 1&2 call	Sverige	Danmark	Finland	Norge
Suksessrate (%)	24	26	25	20
Finansierte prosj.	118	73	58	26

Health 3 call – single stage

	Sverige	Danmark	Finland	Norge
Ant. inst. i søknader	190	101	96	44[^]
Ant. inst. i innstilte prosj.	37	19	16	15[*]

suksessrate = andel finansierte prosjekter i forhold til antall søknader

[^]Antall institusjoner som til sammen deltar i 39 søknader

^{*} Antall institusjoner som til sammen deltar i 12 prosjekter

7RP Norsk deltakelse med suksessrater antall prosjekter registrert per 12.10.2009

eks. 1.trinns søknader ved totrinns prosesser og ugyldige søknader

Program område	Kortnavn	Søknader		Innstilte prosjekter			Suksessrater	
		Tot ant prosjekter	Herav med NO partnere	Tot ant prosjekter	Herav med NO partnere	NO andel av total %	NO suksess-rate %	Ranking over/under snitt i %
Cooperation	HEALTH	2 273	173	416	38	9,1%	22,0%	3,7%
	BIO	1 153	174	190	31	16,3%	17,8%	1,3%
	ICT	3 705	283	571	37	6,5%	13,1%	-2,3%
	NMP	680	70	246	27	11,0%	38,6%	2,4%
	ENERGY	805	105	132	28	21,2%	26,7%	10,3%
	ENVIRONMENT	1 021	192	144	45	31,3%	23,4%	9,3%
	TRANSPORT	1 250	106	286	29	10,1%	27,4%	4,5%
	SSH	882	105	96	14	14,6%	13,3%	2,4%
	SPACE	203	23	45	8	17,8%	34,8%	12,6%
	SECURITY	618	81	83	16	19,3%	19,8%	6,3%
	ERA-NET	23	5	17	4	23,5%	80,0%	6,1%
	Sum:	12 613	1 317	2 226	277	12,4%	21,0%	3,4%



Innovative Medicines Initiative

Joint Technology Initiatives

- Reinvigorate the biopharmaceutical sector in Europe
- *Strategic Research Agenda* developed under the leadership of EFPIA
- Total budget: 1 mill € from FP7 (Health), 1 mill € (in kind) from EFPIA members

IMI

- 1. utlysning: 12 deltakelser fra Norge (i totalt 134 søknader) – En norsk søknad gikk videre til trinn to og denne ble finansiert – område "Understanding severe asthma"
- **2. utlysning**
 - Områdene som skal lyses ut ble gjort kjent i september;
 - oncology, infectious diseases, inflammation, knowledge management.
 - Utlysning 30. oktober
 - Søknadsfrist antagelig 29. januar 2010
 - http://www.imi.europa.eu/calls-02_en.html

Kontaktpersoner

- NCP Health: Berit Nygaard, 22037174, bn@rcn.no
- Programkomité Health:
 - Mari Nes, 22037153, man@rcn.no
 - Maiken Engelstad, HOD
- Økonomi og finans: Yngve Foss, 22037375, yf@rcn.no
- IMI: Hans M. Borchgrevink, 22037160, hmb@rcn.no
- Små og mellomstore bedrifter:
 - Vebjørn Walderhaug, 22037304, vw@forskningsradet.no
 - Erik Hans Eriksen, 22037301, eh@forskningsradet.no